Prescription drug guidelines — coverage criteria for prior authorization, safety edits, and formulary exceptions
Customize your policy alerts
Sign up for all independence_blue_cross policy alerts
Know when independence_blue_cross releases new policies or updates existing guidance.
Monitor payer policy activity
Rules and processes governing coverage, prior authorization, safety edits (age, quantity, MME, stimulant limits), formulary exceptions, and appeals for Independence Blue Cross prescription drug plans administered by a PBM. Applies to members of the Standard Formulary, Select Drug Program Formulary, and Value Formulary.
No material clinical or coverage changes in this revision.
Coverage and Prior Authorization Criteria
Prior authorization and safety edits
Coverage and approvals are contingent on meeting prior authorization criteria and safety edits as evaluated by PBM clinical pharmacists using P&T‑approved criteria.
Clinical pharmacists evaluate requests and may escalate to a medical director if criteria are not met or ambiguous. Incomplete information will delay or may lead to denial; typical decision time is up to 2 business days once complete information is received.
Formulary exception
Formulary exception requests are considered when specific conditions are met.
If approved, the drug is covered at the highest applicable cost-sharing and safety edits (quantity limits, MME and stimulant limits, age limits) still apply.
Coverage for prescriptions that fall outside FDA age guidelines requires prior authorization. Safety edits include age limits; if a prescribed drug is not approved for the member’s age (for example, some agents are FDA‑approved only for individuals age five and older), coverage may be denied until an override is requested and approved. Prescribers may request an age‑limit override when medically necessary. Approval criteria for age‑limit reviews were developed and approved by the Pharmacy and Therapeutics Committee, and providers should initiate prior authorization per the plan’s submission processes.
Prescriptions that fall outside FDA‑approved use or accepted clinical indications may be denied unless a prior authorization supporting medical necessity is submitted and approved. Safety edits are applied to align coverage with FDA labeling and clinical practice guidelines; when a drug’s use is off‑label or otherwise not consistent with these standards, the prescriber must provide documentation during the prior authorization process to justify the clinical use. If the documentation does not demonstrate medical necessity, coverage may be withheld.
Dose Limits and Coding Thresholds
What Providers Must Do
Prior authorization required for select drugs
Independence Blue Cross requires prior authorization for certain covered drugs to confirm medical necessity and appropriate use; PBM clinical pharmacists evaluate requests using Pharmacy & Therapeutics Committee–approved criteria and may escalate to a medical director.
Formulary exception requires trial of ≥3 formulary alternatives
For Value Formulary members, a non‑formulary (formulary exception) request generally requires documentation of a trial of at least three formulary alternatives when available, or documentation of contraindications to those alternatives.
- Complete and fax the non‑formulary exception request form to 1-888-671-5285 with supporting rationale.
- If approved, coverage is at the highest applicable cost‑sharing and safety edits (e.g., quantity limits, MME) still apply.
How to submit prior authorization
Submit prior authorization requests via accepted ePA platforms (e.g., CoverMyMeds, SureScripts), by completing a prior authorization form, or by sending a letter of medical necessity; fax submissions are accepted at 1-888-671-5285.
- PBM will notify the prescribing doctor of approvals or denials by fax, telephone, or letter.
- If clinical pharmacists cannot approve based on criteria, the request will be reviewed by a medical director.
Incomplete prior authorization information delays or risks denial
Incomplete information on a prior authorization request will delay the decision and can result in delayed approval or denial; decisions take up to two business days once complete information is received.
- Provide complete clinical data, dosing and therapy history, and any supporting documentation to avoid delays.
- Incomplete submissions may trigger escalation or denial and prolong member notification.
Background and Rationale
Safety edits are applied to promote safe, appropriate medication use and to align coverage with FDA labeling and clinical guidelines. Key safety edits include age limits (drugs outside FDA age recommendations require prior authorization or an override request), quantity limits (set according to FDA‑approved maximum daily doses, standard dosing, and length of therapy), and cumulative dose thresholds such as opioid MME limits and high cumulative stimulant dose checks. These edits are evaluated by PBM clinical pharmacists using Pharmacy & Therapeutics Committee–approved criteria and may prompt counseling at point of sale, prior authorization review, or escalation to a medical director when necessary.
Key Definitions
Initial Therapy Quantity and Safety Limits
Quantity limits — initial therapy criteria
Quantity limits are applied at initiation and maintenance to align dispensing with FDA‑approved dosing, standard dosing, and safety edits.
Provider must request a quantity limit override via prior authorization for quantities beyond the listed limits.
These limits prevent dispensing of excessive quantities by looking back over the rolling time period.
Maximum daily dose limits are based on FDA‑approved maximum daily dose and formulation.
Day supply limits apply for certain classes (e.g., opioids, butalbital) and may set shorter allowable day supplies for minors; quantity limit override required for exceedance.
Continuation and Renewal Criteria
Continuation/renewal — approval duration and conditions
Prior authorizations and formulary exceptions may be approved for a limited duration; renewal requires action by the provider.
Provider should submit renewal requests prior to expiration to maintain coverage; PBM clinical pharmacists will review renewal requests per established criteria.
Step Therapy Requirements
| Requirement | Details |
|---|---|
| Step-therapy requirement for Value Formulary members | |
| Providers must document trial and failure of at least three formulary alternatives when available, OR document contraindications to those formulary alternatives. | |
| How to request a non‑formulary exception | |
| Complete and fax a non‑formulary exception request form with supporting rationale to 1-888-671-5285. | |
| Coverage and edits if approved | |
| If approved, the non‑formulary drug is paid at the highest applicable cost‑sharing; safety edits such as quantity limits and MME limits still apply. | |
| If denied | |
| Member and provider will receive a denial letter including appeals language. |
Specific Quantity Limits (per fill/unit)
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.